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Abstract: Botulinum neurotoxins (BoNTs) are the most lethal toxins among all bacterial, animal, plant
and chemical poisonous compounds. Although a great effort has been made to understand their
mode of action, some questions are still open. Why, and for what benefit, have environmental bacteria
that accidentally interact with their host engineered so diverse and so specific toxins targeting one of
the most specialized physiological processes, the neuroexocytosis of higher organisms? The extreme
potency of BoNT does not result from only one hyperactive step, but in contrast to other potent
lethal toxins, from multi-step activity. The cumulative effects of the different steps, each having a
limited effect, make BoNTs the most potent lethal toxins. This is a unique mode of evolution of a
toxic compound, the high potency of which results from multiple steps driven by unknown selection
pressure, targeting one of the most critical physiological process of higher organisms.
Keywords: botulinum neurotoxins; Clostridium botulinum; botulism; neuroexocytosis;
SNARE proteins
Key Contribution: Botulinum neurotoxins are the most lethal toxins, the extreme potency of which
results from an accumulation of multiple steps. They are produced by environmental bacteria and
show a large diversity indicating a complex evolution from an unknown origin.
1. Introduction
Botulinum neurotoxins (BoNTs) are the most potent protein toxins among bacterial, animal, plant
and chemical poisonous substances so far known, with a lethal parenteral dose for BoNT type A of
about 0.2–0.3 ng/kg in mice and 1 ng/kg in human [1,2]. A small amount of 30 ng is sufficient to
induce botulism in human adults by the oral route [3]. BoNTs are responsible for botulism, which is a
rare but severe neurological disease characterized by flaccid paralysis, inhibition of secretion, and mild
dysautonomia. Deciphering the poisoning process, how they disseminate in the host body, and what
the different cellular steps of their mechanism of action are have revealed how highly sophisticated
these nano-scale neurotropic weapons are. Several physiologically distinct bacteria produce closely
related types of these deadly poisons. These pathogens are mainly environmental bacterial from soil,
sediments, and occasionally the intestinal content of man and animals. Despite the fact that they have
not developed a strategy to invade and survive in a vertebrate host, these bacteria have evolved to
produce a potent toxin targeting specifically the neuroexocytosis machinery, which is designed to kill a
host at a distance from the site where they replicate and grow. This is a very unusual property. Does
this confer them some competitive advantage favoring the spreading of the neurotoxin genes among
different bacterial species? The aim of this short review is to comment on the different fascinating
aspects of these most potent toxins.
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2. Diversity of Botulinum Neurotoxins and Toxin Complexes
BoNTs are produced as single-chain proteins (~150 kDa, MW). Until one decade ago, only
7 BoNT toxinotypes (A to G), defined by neutralization with corresponding specific antibodies, were
recognized. Then, a chimeric BoNT type FA or HA (also called BoNT/H) was identified in a bivalent
C. botulinum Bh strain responsible for infant botulism [4–6]. This discovery was followed by that of
another putative novel type, called X, in a bivalent C. botulinum B strain, the toxicity of which remains
to be determined [7]. bont gene sequence comparisons have permitted the identification of a large,
still increasing, number of subtypes for each toxinotype (globally more than 40) [8]). For example,
BoNT/A is subdivided into BoNT/A1 to BoNT/A8, BoNT/B into BoNT/B1 to BoNT/B8, BoNT/E
into BoNT/E1 to BoNT/E12, and BoNT/F into BoNT/F1 to BoNT/F8 [8]. Most often, a given toxigenic
strain produces only one BoNT type and subtype. However, some rare strains, called bivalent or
trivalent strains, synthesize two BoNT types such as Ba, Bf, Ab, Af (the lower-case letter meaning that
the corresponding type is produced in a minor amount) [8] (Tables 1 and 2).
All the various types of BoNT are subsequently processed by endogenous or host proteases
into a heavy (Hc) and a light (Lc) chain, linked together by a disulfide bond. Moreover, they are
co-synthetized with one conserved associated protein, NTNH (non-toxic non-hemagglutinin protein,
150 kDa), and several hemagglutinins (HAs) or proteins of unknown properties (OrfX). At the 3D
structure level, NTNH looks very similar to BoNT, except that it is devoid of neurotoxic activity.
The association of a BoNT molecule with a NTNH copy confers to BoNT a long-term stability,
supporting a chaperone activity for NTNH [9]. A large variety of multimeric complexes (referred to as
“botulinum toxin complexes” or “progenitor toxins”) can be formed. Each of them contains only one
copy of BoNT, which can be released upon the exposure of botulinum complex to neutral or mildly
basic pH [10].
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Table 1. Botulinum neurotoxin (BoNT) types, subtypes and producer organisms.
Botulinum Toxin Type BoNT/A BoNT/B BoNT/E BoNT/F BoNT/E BoNT/C BoNT/D BoNT/G BoNT/H BoNT/Ba
BoNT/Bf
BoNT/Ab
BoNT/Af
BoNT/A(B)
BoNT/A2F4F5
Subtypes
A1, A2, A3,
A4, A5, A6,
A7, A8
B1, B2, B3, B5,
B6, B7, B8 B4
E1, E2, E3,
E6, E7, E8,
E9, E10,
E11, E12
F6 F2, F2, F3,F4, F5, F8 F7 E4, E5 C/D, D/C G
H or F/A or
H/A
Enzymatic substrate
(cleavage site)
SNAP25
(QR)
VAMP1, 2, 3
(QF)
SNAP25
(RI)
VAMP1, 2, 3
(QK)
F5: VAMP2 (LE)
VAMP2
(QK)
SNAP25
(RI)
SNAP25
(RA)
Syntaxin
(KA)
VAMP1, 2,
3
(KL)
VAMP1, 2,
3
(AA)
VAMP1, 2,
3
(LE)
Neurotoxin-producing
bacteria C. botulinum C. botulinum
C.
botulinum C. baratii
C.
butyricum C. botulinum
C.
argentinense
C. botulinum
bivalent/trivalent strains
Group Group I Group II Group II Group II Group I Group V Group VI Group III Group IV Group I
Botulism HumanOccasionally animal
Human
Animal not reported
Animal
Very rare in human
No natural
case
reported
Human Human
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Table 2. Putative novel botulinum neurotoxin (BoNT) types and producer organisms.
Botulinum Toxin Type BoNT/X BoNT/I or BoNT/Wo
BoNT/J
or eBoNT/J
or BoNT/En
Cp1 Toxin
(BoNT Homolog)
Subtypes BivalentBoNT/B2-BoNT/X
Enzymatic substrate
(cleavage site)
VAMP1, 2, 3, 4, 5
Ypkt6
(RA)
VAMP2
(WW)
VAMP2
(DL)
SNAP25, 23
(KD)
syntaxin (MD)
Neurotoxin-producing
bacteria
C. botulinum
strain 111
group I
Weisella oryzae Enterococcus faecium Chryseobacteriumpiperi
The putative novel BoNTs have not been reported to be responsible for human or animal botulism.
3. Diversity of BoNT-Producing Bacteria: Clostridia, et al.
To date, the production of BoNTs has been reported in Gram-positive, sporulating anaerobic
bacteria belonging to the Clostridium genus. This is not surprising because among more than
200 Clostridium species, 15 produce very potent toxins, which are responsible for severe diseases
in humans and animals. Since BoNT-producing bacteria share the same phenotype consisting of
producing flaccid paralyzing neurotoxins, most of the neurotoxigenic clostridia have been named
Clostridium botulinum, without consideration of their physiological heterogeneity. Based on phenotypic
markers (e.g., proteolysis, lipolysis, carbohydrate utilization), 16 rRNA gene sequences, and a
whole-genome sequence comparison, neurotoxigenic Clostridia-producing BoNT belongs to at least
six groups (I to VI) corresponding to distinct bacterial species. The so-called C. botulinum strains of
group I produce highly thermoresistant spores and grow between 10 ◦C and 37 ◦C, whereas strains
of group II are non-proteolytic, have moderate thermoresistant spores, and grow and produce toxins
at temperatures as low as 3.5 ◦C. C. botulinum C and D, mainly responsible for animal botulism,
preferentially grow at higher temperature s(37–40 ◦C) and are referred to as group III. C. argentinense,
which produces BoNT/G, is the prototype of group IV. In addition, several other, albeit atypical, strains
of Clostridium species are neurotoxigenic: certain C. baratii strains produce BoNT/F (referred to as
BoNT/F7) and some C. butyricum strains synthesize BoNT/E (referred as BoNT/E4 and E5). They
are assigned to groups V and VI, respectively, and show phenotypic properties related to those of the
corresponding Clostridium species type strains [11,12]. Moreover, the neurotoxigenic strains of each
group or species display a genetic variability. For example, multilocus sequence typing defines several
phylogenetic clusters in each group [13–18].
Moreover, the screening of bont gene sequences in available genomic sequences in databases
have revealed that bont sequences are not restricted to clostridia. Non-clostridial bont homologs
have been identified in other anaerobes and aerobes. bont-like gene clusters have been identified
in Weisella oryzae (referred as BoNT/I or BoNT/Wo), which is a Gram-positive, non-spore-forming,
facultative anaerobe from fermented rice [19], and in Chryseobacterium piperi (referred as BoNT/Cp1),
which is a Gram-negative, non-spore-forming, strictly aerobic bacterium from the environment [20,21].
In addition, an Enterococcus faecium strain isolated from cow has been found containing a bont-related
gene in an OrfX cluster that encodes for BoNT/En. This BoNT, also called BoNT/J, shares a 38.7%
identity with BoNT/X and is more distantly related (23–25% identity) to the other BoNTs and tetanus
neurotoxin (TeNT) [22,23]. The production of functional BoNTs by these non-clostridial microorganisms
has not yet been reported. However, the question of whether BoNTs should still be considered as only
clostridial toxins is now open.
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4. Though Distinct, the BoNTs Cause Similar Diseases
Intoxication with one of the various BoNT types or subtypes causes a unique severe
neurological disease: botulism [24,25]. Overall, the disease results from the inhibition of cholinergic
neurotransmission in the peripheral part of the nervous system. In mammals, botulism is characterized
by mild dysautonomia (including the inhibition of gland secretion) and prominent muscle fatigue
or flaccid paralysis. In the most severe forms, respiratory distress occurs and may be fatal without
treatment. The clinical manifestations of botulism may vary in a subtle manner within the different
toxinotypes and even subtypes. For instance, dysautonomia is more marked after poisoning with
BoNT/B than with BoNT/A [24,25]; type F botulism is also a severe form of botulism but with a
shorter duration compared to type A botulism [26].
Human foodborne botulism, subsequent to the ingestion of preformed BoNT in food, is common in
many countries, such as in Europe. It is mainly caused by types A, B, E and more rarely F. Botulism can
also result from C. botulinum intestinal colonization and subsequent local BoNT production in human
infants (infant botulism is the main form in the US) and more rarely in adults with immature/altered
microbiota. In addition, rarer forms have been reported such as after the colonization of a necrotizing
wound, botulism by inhalation, and iatrogenic botulism. Large outbreaks of animal botulism have
been reported in mammals (e.g., cattle, minks, ferrets, foxes), birds (e.g., waterfowl) due to intoxication
by types C, D, dominantly. Fishes are also susceptible to the disease (types E, B, and C) [12,25,27–30].
5. BoNTs Are Designed to Kill a Distant Host
In most of the infectious bacterial diseases, bacteria colonize the host organism they affect. With
the BoNT-producing bacteria, the situation is very different (Figure 1). Indeed, they produce a toxin
that affects their final targets (i.e., the nerve terminals) in a host living at a distance, spatially and
chronologically, from the site where the bacteria replicate. Foodborne botulism is due to the ingestion
of a preformed toxin contained in inadequately preserved food (human), poorly prepared silage (cattle)
or decaying organic matter or carcasses (many animal species). Live maggots feeding on carcasses can
accumulate enough toxin to cause foodborne botulism in their vertebrate predators, without being
poisoned by BoNTs [31,32]. Remarkably, host intoxication can occur a long time, days up to years, after
the neurotoxin has been synthetized and even after bacterial death, such as in matrices preventing
C. botulinum sporulation, for example, in some canned foods [33,34]. This is possible thanks to the
exceptional stability of the NTNH–BoNT complexes to acidic pH and to proteolytic degradation [9].
Thus, BoNT can pass through the digestive tract (i.e., through the very acidic and protease-rich stomach
as well as the proteolytic intestinal content) in a non-inactivated form. Thereby, BoNTs can cross
without damaging several physiological barriers such as the stomach and intestinal epithelium [35,36].
During foodborne and infant botulism, BoNT molecules undergo passage through the stomach and/or
intestinal epithelium [35,36], either by transcytosis through intestinal epithelial cells [37] or through
the paracellular way thanks to the interaction of HAs with E-cadherin and subsequent disruption
of intercellular junctions [35,38]. Dissemination of BoNTs in the body through blood and lymph
circulation allows BoNT molecules to reach the peripheral nerve endings [35,36]. BoNT cannot gain
direct access to the central nervous system (CNS) across the blood–brain barrier [36,37,39,40]. However,
similarly to TeNT, very minute amounts of BoNT can enter the CNS using a transcytosis mechanism in
neurons via the retrograde pathway [41]. Although BoNT receptors mediating the toxin entry into
target neuronal cells have been extensively analyzed (review in [42]), those driving BoNT sorting into
retrograde transport vesicles remain to be defined.
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Figure 1. Schematic summary of the BoNT activity steps.
6. BoNTs Are Designed to Selectively Recognize Nerve Terminals and Exploit Synaptic Vesicle
Recycling as a Trojan Horse to Enter into Them
What confers the exquisite neurotropic specificity of the neurotoxins? The C-terminus portion
of Hc contains domains mediating binding to target nerve terminals through an interaction with
double membrane receptors comprised of a poly-sialo-ganglioside acting as a low-affinity receptor in
the vertebrates, enriched in the outer leaflet of plasma membranes of neuron nerve endings, and a
high-affinity receptor consisting of a glycoprotein protein (review in [42,43]). It is noteworthy that the
binding affinity of BoNTs for their receptors is in the same range as those of other potent lethal bacterial
toxins (Table 3). Thus, BoNTs are neurotoxins that recognize specific receptors on target neuronal cells,
but they have not developed an exceptional binding affinity to interact with them. Overall, the BoNTs
prefer complex gangliosides rather than a simple one. They have a considerably higher affinity for the
b series gangliosides such as GT1b/GD1b, than with GM1 or GM3; binding to GD1a is high as well
(review in [40,42]). The preference for gangliosides varies with the toxinotype. For instance, the affinity
of BoNT/A is high for GT1b > GD1b >> GM1 [44]. BoNT/B affinity is high for GT1b and GD1a and
much lower for GD1b and GM1 [45] and that of BoNT/F is higher for GT1b and GD1a than for GM3
and very low for GD1b or GM1a [46]. Of interest, the dominant forms of gangliosides in neurons are
the complex forms including GM1, GD1a, GD1b, and GT1b, which are more enriched (1 to 2 order of
magnitude higher) in nerve cell membranes than in other cell types [47,48], thereby explaining BoNT
tropism for the nervous system.
Depending on the BoNT toxinotype, the protein receptor is one of the vesicle membrane proteins:
N-linked glycan-SV2 (-A, -B, or -C) or synaptotagmin (−1 or −2). This interaction with a dual
receptor on cell membrane avoids the binding of BoNT to non-receptive cells and facilitates specific
trapping from the extracellular space and concentration into neuron endings. The two binding
sites for gangliosides and glycoprotein, respectively, have been characterized on the HcC-terminal
domain [42,43]. Interestingly, BoNT interaction with SV2 isoforms requires both the recognition of a
protein domain and a glycan N-lined to SV2 [49,50]. The recognition of N-linked glycan in addition to
the protein part of a receptor increases the specificity of the host–pathogen or bacterial toxin interaction
with target cells [51]. BoNT/B, D/C, and G, w ich interact with synaptotagmi , use an addi ional
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interaction with the lipid membrane via a hydrophobic loop located in their Hc between the ganglioside
and synaptotagmin binding sites [52]. Moreover, both co-receptors (poly-ganglioside + protein) have
to be co-localized into the same membrane microdomain [53]. Thus, during evolution, Hc looks to be
tuned for maximizing the interaction of BoNT with neuron endings, thereby facilitating its ensuing
neuronal uptake. Indeed, SV2 and synaptotagmin are integral proteins of synaptic vesicle membrane
whose luminal domain is exposed onto the nerve-ending surface upon the collapse of synaptic vesicles
with the plasma membrane during neurotransmitter exocytosis. This allows the trapping of BoNT
inside recycling synaptic vesicles, the acidification of which triggers the translocation of Lc into the
cytosol, and at the same time, the disulfide bridge linking Lc to Hc is reduced, making Lc free in
the cytosol and unmasking its catalytic cleft [42,54–57]. Hence, recycling synaptic vesicles act as the
main Trojan horse (Figure 1) that introduces the neurotoxins into the nerve terminals at only a few
tens or even hundreds of nanometers from the site where their final molecular targets, the soluble
N-ethylmaleimide-sensitive-factor attachment protein receptor (SNAREs), are concentrated.
Table 3. Binding affinity to receptor of Botulinum neurotoxins (BoNT) and representative potent lethal
bacterial toxins.
Toxin Neuronal Membrane/Receptors Kd Affinity Reference
BoNT/A SV2C, neurons 0.46 nM [58]
BoNT/B Rat synaptotagmin/GT1b, rat brainsynaptosomes ≈0.4 nM [59]
BoNT/B Mouse synaptotagmin IIHuman synatotagmin II
130 nM
>20 µM [60]
Diphtheria toxin (DT) Heparin Binding-EGF 1.3 nM [61]
Diphtheria toxin LCH cells (L cells expressing DTreceptor) 0.56 nM [62]
Protective antigen
Bacillus anthrax toxin
Capillary morphogenesis protein 2
(CMG2) 0.17 nM [63]
Anthrax toxin receptor/tumor
endothelial marker 8 (ATR/TEM8) 130 nM [64]
Clostridium perfringens
epsilon toxin Rat brain synaptosome 2.5 nM [65]
Clostridium sordellii lethal
toxin Porcine brain phosphatidyl serine 140 nM [66]
7. BoNTs Are Not Super-Enzymes but Their Effect Is Amplified at Many Steps of Their Action
Lc is a Zn-dependent metalloprotease [67]. In the cytosol, depending on the BoNT toxinotype,
Lc specifically cleaves only one of the three SNARE proteins (either synaptosomal nerve-associated
protein 25 (SNAP-25), vesicle-associated membrane protein (VAMP)/synaptobrevin, or syntaxin)
(Table 1). The high proteolytic specificity of Lc for a unique substrate results from a pairing of one to
two SNARE motifs (in addition to the cleavage site) with exosites present in the Lc catalytic cleft [68–70].
Given the key role for the SNAREs in mediating the fusion of synaptic vesicles with plasma membrane
exocytosis, their cleavage results in a blockade of Ca2+-dependent exocytosis of neurotransmitters
(Figure 1).
Not only BoNTs inhibit neurotransmission, but they also do it over a long term. Indeed, whereas
the lifespan of these neurotoxins in extracellular media is in the range of several days, this is not the case
when they are intra-neuronal. Here, their lifespan is in the range of several weeks to months (reviewed
in [71]). The longest-acting one is BoNT/A Lc. Its interaction with a cytosolic des-ubiquitin ligase
prevents its ubiquitinylation and ensuing entry into the proteasome degradation pathway [72–74].
This allows for maintaining the inhibition of exocytosis for months, despite the rapid re-synthesis
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of the cleaved SNAREs. However, the lifetime of Lc in neuronal cells is probably not the only factor
involved in the duration of BoNT effects. Indeed, SNARE complexes likely adopt a radial arrangement,
and this supports the idea that SNAP25 cleaved by BoNT/A does not impair the SNARE complex
assembly but acts as dominant negative SNARE oligomer that can have a long-duration inhibitory
effect on neuroexocytosis machinery [75,76].
As mentioned above, BoNTs undergo a long journey between the distant site of their production
(mostly in food or intestine) and the nerve endings where they act (Figure 1). Along this journey,
they pass through several physiological barriers at the price of large dilution in body fluids, so that
only tiny amounts reach nerve terminals (far below picomolar concentrations during the disease).
Therefore, with regard to their very high lethality (a range of 100 million mice LD50/mg neurotoxins;
LD ~0.2 ng/kg in case of BoNT/A), one would expect their Lc to be a super protease. However, this is
not the case. Their enzymatic kinetic parameters, as investigated with BoNT/A Lc and its substrate
SNAP25, revealed an enzymatic performance which is far from exceptional. The number of SNAP25
molecules cleaved by a BoNT/A Lc molecules per second (kcat) is rather low (kcat = 17.1 s−1 [77,78],
kcat = 0.51 mn−1 (0.0085 s−1) [79]). This is slightly lower than other bacterial proteases (kcat of
thermolysin-like zinc-dependent protease of Bacillus stearothermophilus = 180 s−1) [80]. Why are BoNTs
so deadly? It turns out that their incredible lethality results from a unique combination of two factors.
First of all, the neurotoxins attack our Achilles’ heel: the system of communication between neurons
and essential effectors such as muscles and glands, without which life cannot occur. Second, many
steps optimize or even amplify their deleterious action (Figure 1):
(i) The chaperoning of BoNT by NTNH minimizes acidic pH and protease degradation upon passing
through the upper digestive tract;
(ii) Receptor-mediated transcytosis and/or HA-dependent paracellular passage allows the bypassing
of physiological barriers (intestinal barrier or endothelial barrier);
(iii) Specific receptors on neuronal cells trap and concentrate the toxin molecules on target cells
avoiding diffusion and dilution in non-productive host compartments;
(iv) Receptor-mediated internalization by recycling vesicles optimizes neurotoxin uptake at the
precise site where their molecular targets (the SNAREs) are accumulated;
(v) Nerve endings contain hundreds (most central synapses) up to several tens of thousands
(motoneuron) of synaptic vesicles. Their fusion with a plasma membrane can occur only in
very specialized regions (i.e., release sites) of the plasma membrane called active zones, the
number of which is limited at each nerve ending. For a fusion event, a ring of several SNARE
complexes should be formed at the interface of a given synaptic vesicle and plasma membrane at
the release site [81]. Following cleavage by BoNT, SNAREs can form non-productive complexes.
Therefore, synaptic vesicles can continue docking on release sites but do not fuse due to the
presence of one or a few unproductive SNARE complexes in the ring [40,81]. Since these vesicles
cannot fuse nor be retrieved, the number of release sites able to experience exocytosis decreases,
as demonstrated after the cleavage of VAMP/synaptobrevin [82]. Thus, the cleavage of a small
proportion of the SNAREs is sufficient to silence synaptic neurotransmission [40,81];
(vi) The long duration of the Lc of some BoNT types such as BoNT/A, which is the most potent BoNT,
inside the target cells and the long duration of activity;
(vii) At the neuromuscular junction, there is no need for a complete blockade of exocytosis to get
complete paralysis [83]. As soon as the number of synaptic vesicles fusing with plasma membrane
in response to motor command is too low to induce subthreshold post-synaptic responses, muscle
fiber contraction does not occur and muscle contraction weakens;
(viii) Asphyxia and subsequent death do not need the complete paralysis of the diaphragm and
pharyngeal muscles. It occurs when muscle weakness is sufficient not to allow enough gas
exchange (i.e., a vital capacity below 15 mL/kg body weight in humans) as reported for peripheral
neuropathies [84]. This may explain why the lethal dose of BoNT/A in mice (25 g) by the
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intraperitoneal route is 3.7 pg [85] or 7 pg for highly purified recombinant toxin [86], whereas the
ex-vivo nerve-hemidiaphragm assay requires 10 to 20 more toxin molecule numbers [87].
Overall, BoNTs are not super enzymatically active but super efficient (Figure 1). Their very
high potency results from a unique combination of in vivo steps, each with a limited incremental
effect, the accumulation of which confers to this non-cytotoxic toxin the ability to kill large organisms.
This situation is unique among bacterial toxins. The other bacterial toxins that display high lethal
toxicity just below the BoNTs are diphtheria toxin, Clostridium perfringens epsilon toxin and Clostridium
sordellii lethal toxin [88]. In contrast to BoNTs, they are highly cytotoxic for their target cells, and this
critical step is responsible for their pathological effects [89–93].
8. What about the BoNT Origin?
A large number of distinct bacteria share the same property of producing a BoNT, albeit of diverse
types or subtypes. This raises the question of the origin of the BoNTs. The high level of amino acid
sequences and the structural identity of all the BoNTs types and subtypes as well as NTNH proteins
associated to BoNTs strongly support the possibility that they derive from a common ancestor gene.
What are the gene spreading mechanisms involved in making so many different bacterial strains
produce BoNTs or display bont-related genes? bont genes and those encoding non-toxic associated
proteins (NTNH, HAs, or OrfX) are localized in a locus (botulinum locus) which is flanked by insertion
sequences and is located in various DNA structures (chromosome, plasmid, phage, transposon or
transposon-like DNA elements). Such a localization of DNA mobile elements, notably plasmid and
phages, accounts for horizontal gene transfer between various clostridial strains [94–96], and possibly
also between clostridia and other bacterial species. For instance, the gene of the novel BoNT/En
(i.e., BoNT/J) is located in the E. faecium conjugative plasmid possibly acquired from a Clostridium
strain [23]. In most of the C. botulinum B strains, the botulinum locus is located in plasmids and
shows a high genetic diversity even inside each subtype [97]. In addition, most of the clostridial
bivalent strains include a botulinum locus type B, suggesting that these strains are highly receptive
to the acquisition/transfer of mobile elements such as plasmids and are highly susceptible to DNA
modifications [95,98,99]. C. tetani produces a TeNT that is closely related to BoNT/B and shares with it
the same cleavage site in its SNARE target [67]. Similar to the bont B gene, the tent gene is also located
on a large-sized plasmid, and BoNT/B shares the highest level of its amino acid identity with TeNT.
However, tent is not associated with non-toxic protein encoding genes. Therefore, the question of
whether BoNT/B results from genetic transfer and the subsequent modification of tent from C. tetani,
or vice-versa, is open. Interestingly, the ntnh gene is conserved in all BoNT-producing clostridia and is
located just upstream of the bont gene with which it forms an operon, supporting the idea that bont
and ntnh result from duplication of a common ancestor gene. Indeed, NTNH retains the same size
as BoNT, and both NTNH and BoNTs are structurally related [9,39]. Is there a common ancestor of
clostridial neurotoxin genes with duplication in bont and ntnh genes in C. botulinum in contrast to the
single tent gene in C. tetani? It has been hypothesized that the clostridial neurotoxins have arisen from
a viral protease fused to transmembrane and receptor domains [100]. However, the mode of genetic
transfer between virus and clostridia is hypothetical. C. botulinum C and D contain phages harboring
bont, but these phages share no significant homology with other phages or viruses [101].
9. Distribution of BoNT-Producing Bacteria
Until now, the established BoNT-producer has been clostridia. The usual habitat of clostridia is an
anaerobic environment: soil, dust, sediment, cadavers, manure, and, depending on the species, the
intestinal content of healthy animals (mammals such as, pigs, birds, and fishes). Although C. botulinum
strains are widely distributed in the environment, there still exist geographical variations in the
prevalence of certain toxinotypes. Type A and B strains are found in soils that are poor in organic
matter, and more rarely in aquatic sediment. Overall, C. botulinum type A is predominant in the
western part of the United States (west of the Missouri and Mississippi rivers), in soil that is neutral
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to alkaline (average pH 7.5) with a lower than average organic content. In contrast, type B prevails
largely in the eastern part of the United States, and central and western Europe. B strains are recovered
in slightly more acidic soil and sediments (average pH 6.25) with a higher level of organic matter
content, and mainly in cultivated soils (pasture, fields) [102–104]. Group II C. botulinum strains (C.
botulinum E, non-proteolytic C. botulinum B and F) can grow and produce toxin at low temperatures.
Therefore, C. botulinum E is predominant in the northern part of Europe (Scandinavia, Finland),
America (Canada, Alaska) and Asia [103] whereas C. botulinum B from group I and unexpectedly also
from group II are more prevalent in warmer areas. Moreover, C. botulinum B is a frequent inhabitant
of the digestive tract of healthy pigs while C. botulinum E is often found in the intestinal content of
fish and aquatic animals living in northern countries [103,105,106]. Thus, BoNT-producing clostridia
show certain distinct environmental distributions that reflect their different physiological properties
better than the production of different BoNT types. The distribution of the non-toxic C. botulinum
counterparts has not been thoroughly investigated. It is noteworthy that clostridia are widespread
in the environment. For example, clostridia, and notably C. butyricum, are one of the most abundant
bacterial groups in lake sediments and sludge [107,108]. Based on their physiological properties,
such as their tolerance/sensitivity to oxygen, the requirement of an appropriate pH, temperature,
substrate for growth, and spore production/germination, the repartition of Clostridium species in the
environment is heterogeneous. Saccharolytic clostridia such as C. butyricum and C. baratii preferentially
grow in carbohydrate-rich environments, notably in decomposing vegetables and fruits, whereas
proteolytic and gelatinolytic Clostridium including toxigenic and non-toxigenic C. botulinum strains that
poorly sporulate are mainly found in animal cadavers or soil/sediments rich in organic material [12].
The basis of the adaptation of metabolic pathways to particular substrates and/or to host defenses by
the distinct C. botulinum types and subtypes remain to be elucidated.
10. Why So Potent, and for What Purpose?
A current idea is that the production of potent toxins able to kill specific animal hosts might
facilitate the survival and dissemination of BoNT-producing strains in the environment by providing
appropriate substrates from animal cadavers [31,32]. Is this, overall, the case with neurotoxigenic
clostridia? Apparently not: the non-toxigenic strain derivatives by the loss of bont genes (loss
of phage, plasmid, and mobile DNA elements, for example) can grow and sporulate as well as
their neurotoxigenic counterparts. In addition, the toxigenic strains closely related to non-toxigenic
clostridial species are widespread in the environment, further arguing that toxigenicity is not a
prerequisite of survival in the environment [97,98]. The most striking example is Clostridium sporogenes,
which is commonly considered as a non-toxic counterpart of group I C. botulinum strains. The genomic
analysis of C. sporogenes shows that most strains, albeit highly related (93% average nucleotide identity)
to C. botulinum group I strains, contain specific clade-genetic signatures and constitute a distinct
bacterial species than C. botulinum. However, some C. sporogenes strains have lost these signatures
and are phylogenetically clustered with C. botulinum group I strains [97,109]. Horizontal bont gene
transfer has been demonstrated between strains from C. botulinum group I and C. sporogenes, further
supporting the high genetic relatedness between them [96]. C. sporogenes is a frequent inhabitant of
the environment, notably in milk, milk products, and canned foods [110,111], and is widely used
as a C. botulinum surrogate in testing commercial food processing procedures [112,113]. This again
further supports the idea that bont does not confer a specific advantage in Clostridium’s survival and
spread in the environment. Therefore, what is the evolutionary pressure driving bont gene-spreading
in a number of bacterial species (as mentioned above)? Moreover, we face another unusual situation:
BoNT-producing bacteria live in an anaerobic environment and their toxins act on very distant hosts
living in an aerobic environment. Even in the case of wound botulism [25], the anaerobic environment
in which they grow (necrotic abscess) is not due to BoNT action but to the favorable conditions of
necrotic tissue similar to those that can be found in the natural environment. The intestinal content is
also an anaerobic environment, but the physiological microbiota is not favorable to the growth of these
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environmental bacteria [32]. It is worthwhile to note that the BoNTs responsible for the most frequent
forms of foodborne botulism in human and cattle are produced in preserved food (type A and B for
humans) and silage (type C, D for cattle), which are recent human artefacts, which cannot have been
anticipated by evolution.
Are vertebrates the only possible hosts? The SNAREs are evolutionarily highly conserved among
all eukaryotes [114]. However, the SNAREs harboring the cleavage sites attacked by BoNT or the
closely-related TeNT look to appear with the nervous system of the metazoans, which exploit the
Ca2+-regulated exocytosis of neurotransmitters, mediated by a specific subset of SNAREs and using
synaptotagmin as a Ca2+-sensor. Indeed, SNAREs susceptible to cleavage by BoNT or TeNT are
expressed in the neurons and endocrine cells of many invertebrate and vertebrate phylla. Intracellular
neurotoxin or Lc expression bypassing the limiting membrane steps leads to exocytosis inhibition in
Echinoidea (as sea urchin), Annelida (as the leech), Mollusca (as Aplysia, squid), Arthropoda (as crayfish
or the fruit fly Drosophila), and in almost all the vertebrates (fish, birds, mammals) [40,81]. Therefore,
all metazoans are potential sensitive hosts for BoNTs. However, harboring a cleavable SNARE is
not sufficient for designing a potential host. Indeed, invertebrates look not to be susceptible to
botulism [31,115,116] and the impairment of neurotransmission in them needs a very high extracellular
concentration of BoNT (10 nM in A. californica) [117]. Indeed, a key limiting step in the poisoning
mechanisms is receptor-mediated internalization. Although the protein receptors of some BoNTs, such
as synaptotagmins (−1, −2), are well conserved during evolution; this is not the case for N-linked
glycan SV2 isoforms that are lacking in invertebrates (although vertebrates and invertebrates shares
the non-glycosylated SV2-related-protein SVOP [118]). Moreover, invertebrates, except echinoderms,
do not synthetize the gangliosides [48] that increase BoNT’s binding affinity to neurons. Hence,
the victims/hosts of prototypic BoNTs in natural conditions seem to be members of the vertebrata
sub-phylum and not invertebrates. However, it is conceivable that, during evolution, the binding
domain in BoNT Hc may have evolved to facilitate the exploitation of other membrane receptors,
allowing these modified toxins to attack the invertebrate nervous system. If so, what would be the
clinical manifestations of the disease in invertebrates?
It is difficult to conceive of what kind of evolutionary pressure pushed the clostridia to develop
such sophisticated neurotropic weapons, with the ultimate ‘purpose’ of killing animals and moreover
at a distance from the bacterial multiplication site. Is this to create, from time to time, a large
anaerobic fermentor [32]? Perhaps we are barking up the wrong tree: indeed, the production of
BoNT might be a “quality” independent from bacterial survival, as recently proposed [119], which
does not confer any advantage to the bacteria. Thereby, botulism might be the result of accidental
encounters between unfortunate receptive hosts and neurotoxigenic environmental bacteria rather
than a beneficial and prerequisite interaction for the pathogen. However, this type of accident looks to
be highly frequent enough to have exerted some evolutionary pressure on the hosts: SNARE mutations
conferring resistance to cleavage concentrates in certain highly exposed animal species (rat and chicken
VAMP-2 [40,67,81]. Does the genetic diversity of clostridia strains and corresponding BoNT variants
involved in the various forms of botulism (foodborne, infant, intestinal, and wound botulism) reflect
the fact that the strains are found in the environment where the host is living rather than a pathogen
adaptation to a specific host [18,33,120,121]? Since bont-related genes have been recently identified
in other bacteria than Clostridia (see above Section 3), it is conceivable that BoNT-ancestor related
toxins and corresponding hosts will be discovered in the future, shedding light on the evolutionary
mechanisms pushing many bacteria to adopt such a potent toxin arsenal.
11. Concluding Remarks
It is to our discredit that we have failed to answer the introductory questions: the mystery still
remains. Indeed, what the protease ancestor gene could be that gives rise to the unique situations that
different bacteria share closely related toxins remains to be elucidated. Even more enigmatic is why
and how environmental bacteria have acquired such sophisticated and active toxins characterized
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by extreme specificity towards highly specialized proteins from the metazoan neural machinery
of neuroexocytosis. What is the advantage for them to produce a lethal toxin that can kill a host
at a distance from the bacterial replication site? Since the identification of botulism as a natural
poison-caused disease by Justinus Kerner [122,123], two centuries of hard work have been necessary
to understand botulism’s mechanisms at the molecular level. The natural history of the BoNTs
and their producing bacteria is still in progress. From the suspicion of a neurotoxic compound
in some contaminated foods responsible for a severe neurological disease to the characterization
of BoNT activity in the neuroexocytosis process at the molecular and structural levels, a major
breakthrough has been reached. However, a complete understanding of these toxins, which show a
great diversity and use a sophisticated multi-step activity to become the most potent toxins, remains to
be further developed.
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